31-45 of 379
Myeloid Mutations in ALL: Disease Risk and Prognostic Implications
Project Oncology®Myeloid Mutations in ALL: Disease Risk and Prognostic Implications
Caner Saygin, MD
Moving Beyond Chemotherapy in Mantle Cell Lymphoma Care
Project Oncology®Moving Beyond Chemotherapy in Mantle Cell Lymphoma Care
Jonathon Cohen, MD, MS
How Myeloid Mutations in ALL Inform Treatment Decisions
Project Oncology®How Myeloid Mutations in ALL Inform Treatment Decisions
Caner Saygin, MD
Key Questions Shaping Chemotherapy-Free Treatment in Mantle Cell Lymphoma
Project Oncology®Key Questions Shaping Chemotherapy-Free Treatment in Mantle Cell Lymphoma
Jonathon B. Cohen, MD, MS
Bruno Batinica, MD
Advancing ATTR-CM Identification: Early Findings from TRACE-AI
Heart MattersAdvancing ATTR-CM Identification: Early Findings from TRACE-AI
Bruno Batinica, MD
- advertisement
The Role of TTR Stabilization in ATTR-CM Treatment
On the Frontlines of ATTR-CMThe Role of TTR Stabilization in ATTR-CM Treatment
Steve Jackson, PharmD
Sumeet Mitter MD, MSc, FACC
Sumeet Mitter MD, MSc, FACC
Multidisciplinary Care in ATTR-CM: Building the Right Team
Heart MattersMultidisciplinary Care in ATTR-CM: Building the Right Team
Sumeet Mitter MD, MSc, FACC
Building Clinical Expertise in ATTR-CM Management
Heart MattersBuilding Clinical Expertise in ATTR-CM Management
Sumeet Mitter MD, MSc, FACC
The Future of ATTR-CM Care: A Look at What's Next
Heart MattersThe Future of ATTR-CM Care: A Look at What's Next
Sumeet Mitter MD, MSc, FACC
Counseling Patients on Myelofibrosis Treatment Goals and Expectations
Project Oncology®Counseling Patients on Myelofibrosis Treatment Goals and Expectations
Shelina Ramnarine, PhD
John Mascarenhas, MD
Marina Kremyanskaya, MD
- advertisement
Recognizing Atypical Presentations of Inflammatory Dermatoses
DermConsultRecognizing Atypical Presentations of Inflammatory Dermatoses
Alexandria May, PharmD, BCPS
Naiem T. Issa, MD, PhD, FAAD
The Long Road to an FCS Diagnosis
On the Frontlines of Familial Chylomicronemia SyndromeThe Long Road to an FCS Diagnosis
Charles Turck, PharmD, BCPS, BCCCP
Peter P. Toth, MD, PhD, FAAFP, FICA, FAHA, FNLA, FCCP, FACC
Could It Be FCS? Recognizing the Diagnostic Clues
On the Frontlines of Familial Chylomicronemia SyndromeCould It Be FCS? Recognizing the Diagnostic Clues
Mary Katherine Cheeley, PharmD, BCPS, CLS, FNLA
Zahid Ahmad, MD, FNLA